XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.2
SEGMENT INFORMATION
 6 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
We are organized into three reporting segments. Operations that sell proprietary dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets form our Aptar Pharma segment. Operations that sell dispensing systems and sealing solutions to the beauty, personal care and home care markets form our Aptar Beauty segment. Operations that sell dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets form our Aptar Closures segment. Aptar Pharma and Aptar Beauty are named for the markets they serve with multiple product platforms, while Aptar Closures is named primarily for a single product platform that serves all available markets.
The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2023. We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.
Financial information regarding our reporting segments is shown below:
Three Months Ended
June 30,		Six Months Ended
June 30,
2024202320242023
Total Sales:
Aptar Pharma$414,783 $391,010 $822,273 $747,121 
Aptar Beauty328,700 338,404 663,580 671,742 
Aptar Closures176,981 177,471 359,678 357,910 
Total Sales$920,464 $906,885 $1,845,531 $1,776,773 
Less: Intersegment Sales:
Aptar Pharma$250 $310 $447 $375 
Aptar Beauty7,213 8,817 14,773 15,766 
Aptar Closures2,938 1,852 4,800 4,659 
Total Intersegment Sales$10,401 $10,979 $20,020 $20,800 
Net Sales:
Aptar Pharma$414,533 $390,700 $821,826 $746,746 
Aptar Beauty321,487 329,587 648,807 655,976 
Aptar Closures174,043 175,619 354,878 353,251 
Net Sales$910,063 $895,906 $1,825,511 $1,755,973 
Adjusted EBITDA (1):
Aptar Pharma$141,488 $125,866 $273,666 $235,164 
Aptar Beauty44,638 43,100 85,772 80,305 
Aptar Closures27,118 27,772 54,279 53,780 
Corporate & Other, unallocated(20,476)(15,501)(42,117)(34,337)
Acquisition-related costs (2)(140)— (140)(255)
Restructuring Initiatives (3)(2,315)(1,943)(5,795)(13,467)
Net unrealized investment (loss) gain (4)(140)2,891 452 3,079 
Depreciation and amortization(64,968)(62,267)(129,317)(121,526)
Interest Expense(10,061)(9,688)(20,236)(19,916)
Interest Income3,102 648 6,000 1,320 
Income before Income Taxes$118,246 $110,878 $222,564 $184,147 
________________________________________________
(1)We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.
(2)Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 17 - Acquisitions and Note 18 – Investments in Equity Securities for further details).
(3)Restructuring Initiatives includes expense items for the three and six months ended June 30, 2024 and 2023 as follows (see Note 19 – Restructuring Initiatives for further details):
Three Months Ended
June 30,		Six Months Ended
June 30,
2024202320242023
Restructuring Initiatives by Plan:
Optimization initiative$2,315 $1,943 $5,812 $13,483 
Prior year initiatives— — (17)(16)
Total Restructuring Initiatives$2,315 $1,943 $5,795 $13,467 
Restructuring Initiatives by Segment:
Aptar Pharma$65 $434 $89 $1,565 
Aptar Beauty1,199 479 3,909 9,770 
Aptar Closures893 440 1,653 962 
Corporate & Other158 590 144 1,170 
Total Restructuring Initiatives$2,315 $1,943 $5,795 $13,467 
(4)Net unrealized investment (loss) gain represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details).